KRAS mutational analysis for colorectal cancer

PLoS Curr. 2010 Sep 2. pii: RRN1175.
KRAS mutational analysis for colorectal cancer: Application: Pharmacogenomic.

Wang G, Kelley RK, Gappnet.

Center for Translational and Policy Research on Personalized Medicine (TRANSPERS), University of California, San Francisco and University of California, San Francisco.

Abstract

KRAS mutational analysis is a genetic test used in clinical practice for determining the status of the KRAS gene (wild type or mutant) in tumors from patients with metastatic colorectal cancer (CRC). Persons whose tumors are wild type may respond to therapies cetuximab (Erbitux) or panitumumab (Vectibix).

PMID: 20877448 [PubMed - in process]PMCID: PMC2940138Free PMC Article

full-text:
KRAS mutational analysis for colorectal cancer